Medicine procurement and pricing policies are foundational to South Africa’s approach to equitable healthcare access. As the country contends with growing demands for chronic disease care, global cost pressures, and constrained public budgets, it becomes increasingly important to improve procurement systems that promote both sustainability and consistent supply across all levels of healthcare.
South Africa’s public sector medicine procurement system is among the largest and most organised on the continent. Through centralised tendering managed by the National Department of Health (NDoH), the state is able to secure bulk pricing on treatments for high burden conditions, this system supports broader access by lowering acquisition costs through pooled demand and long-term contracting. While this framework can support significant per-unit savings through volume-based procurement, the impact of these pricing advantages relies heavily on timely execution and the efficiency of distribution.
A key operational challenge within public procurement lies in payment efficiency. Suppliers frequently cite late payments and budget uncertainties as contributing factors to medicine supply delays. These issues can be especially challenging for smaller or locally based pharmaceutical providers that lack the financial flexibility to continue fulfilling orders without or delayed payment. When cash flow disruptions occur, they can lead to supply gaps and delayed deliveries. Strengthening financial governance, improving payment predictability, and ensuring transparency in procurement workflows are critical enablers of supply stability.
Tender cycle design is another important consideration. In the public sector, multi-year tenders, often spanning two to three years, are used to stabilise pricing and create predictability for both buyers and suppliers. However, these extended timelines can limit responsiveness to changes in exchange rates, treatment guidelines, and global supply conditions. Furthermore, if contract awards or supplier onboarding are delayed at the start of a cycle, facilities may face temporary stock disruptions. In these instances, alternative procurement through emergency channels or retail sources can come at higher cost to the system.
The private sector operates under a distinct pricing model governed by the Single Exit Price (SEP) framework which was introduced in 2004. SEP regulates the base manufacturer price of medicines sold in the private market, to which a logistics fee and VAT are added. This model helps reduce unwarranted price variation and introduces greater transparency into private sector pricing. However, it is worth noting that SEP applies solely to the private sector, and public sector procurement is managed independently through tender processes.
While the public sector pricing framework often benefits from scale through volume-based procurement, the true value of these arrangements hinges on effective execution. Timely tender awards, predictable supplier payments, and coordinated downstream distribution are critical to translating negotiated prices into actual medicine availability. Factors such as aggregated demand, patent limitations, and the speed at which generics enter the market all influence pricing and access trends across categories. Strengthening these systemic elements is essential to maximise the impact of public procurement on equitable healthcare access.
Rather than direct price comparisons between sectors, the focus should be on creating complementary procurement strategies that strengthen access in both. A data-driven procurement mode, one that includes accurate demand forecasting, real-time inventory tracking, and integrated supply chain systems, could reduce stock variability, improve order accuracy, and limit emergency procurement needs. Similarly, enhanced supplier performance monitoring based on delivery timelines, compliance, and quality standards can support more proactive contract management.
Opportunities also exist to evolve contracting approaches. Hybrid contracts that account not only for price but also for supply reliability, quality assurance, and flexibility during supply shocks could offer better value over time. In some contexts, outcome-based procurement or usage-based pricing agreements, already being tested internationally, could help balance affordability with innovation, particularly for high-cost or new therapies.
On a regional level, South Africa is well positioned to lead collaborative procurement efforts. Initiatives such as pooled procurement across SADC or through the African Medicines Agency could expand supplier interest, enhance negotiating power, and support cross-border supply security. Experiences from antiretroviral procurement have already demonstrated the power of such collaboration in achieving consistent access and predictable pricing.
Ongoing assessment of the public sector pricing framework including logistics fee structures, supplier payment timelines, and generic uptake policies can help ensure that affordability objectives are met. Policies that expand access to cost-effective medicines and promote consistent prescribing practices at facility level remain essential. Strengthening alignment between regulatory approval processes and procurement cycles will further enhance the availability and timely distribution of essential medicines across the public healthcare system.
Ultimately, the efficiency of any procurement system depends not just on price negotiation, but on how well it aligns with access goals. Reliable supply, transparent processes, and system wide integration are foundational to both equity and sustainability. This includes ensuring that medicines registered through the regulator are procured in a timely manner, that payment systems enable supplier continuity, and that long-term planning incorporates risk management for supply disruptions.
South Africa’s public health system has shown strong leadership in using pooled procurement to increase medicine access. With enhanced systems, responsive contracting models, and stronger inter-agency collaboration, it can further strengthen this foundation ensuring that affordability and accessibility remain mutually reinforcing goals, rather than competing pressures.